Physician profile
Daniel M Hardy
NPI 1932179462
$382,169.54
in general payments reported to CMS, 2019-2025
75 companies · $97K in 2025
The $97K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $13K · 2021: $53K · 2022: $81K · 2023: $50K · 2024: $48K · 2025: $97K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $169K · Food and Beverage: $16K · Travel and Lodging: $5,769 · Consulting Fee: $3,314 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $168,817.50 |
| Food and Beverage | $16,106.26 |
| Travel and Lodging | $5,768.57 |
| Consulting Fee | $3,314.00 |
| Education | $287.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $200,678.51 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $79,708.13 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Abbvie INC. | $47,518.40 | 2019-2025 | |
| Pfizer INC. | $19,729.84 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $14,766.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,863.36 | 2022 | |
| Ucb, INC. | $1,767.11 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Allergan, INC. | $1,091.46 | 2019-2022 | |
| Genentech USA, INC. | $931.76 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $899.99 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $637.92 | 2019-2025 | Ultomiris, Soliris |
| Amgen INC. | $614.34 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $596.37 | 2019-2024 | |
| Sk Life Science, INC. | $464.42 | 2022-2025 | |
| Celgene Corporation | $408.18 | 2021-2025 | Zeposia |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $383.43 | 2019-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $342.19 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $328.76 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Amneal Pharmaceuticals LLC | $296.74 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Harmony Biosciences LLC | $277.83 | 2020-2025 | Wakix |
| Eisai INC. | $277.66 | 2020-2025 | |
| Grifols USA, LLC | $252.90 | 2019-2025 | Gamunex-C |
| Tg Therapeutics, INC. | $241.20 | 2023-2025 | |
| Neurelis, INC. | $232.98 | 2021-2025 | Valtoco |
| Mdd US Operations, LLC | $228.77 | 2019-2024 | Gocovri, Gocovri |
| Kyowa Kirin, INC. | $214.05 | 2019-2024 | Nourianz |
| Sunovion Pharmaceuticals INC. | $198.92 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $175.12 | 2021-2024 | Acthar |
| Acadia Pharmaceuticals INC | $157.01 | 2019-2024 | Nuplazid |
| Argenx US, INC. | $154.28 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Janssen Biotech, INC. | $146.59 | 2025 | |
| Neurocrine Biosciences, INC. | $144.92 | 2019-2025 | Ingrezza, Ongentys |
| Csl Behring | $132.89 | 2019-2023 | Hizentra |
| Jazz Pharmaceuticals INC. | $132.62 | 2021-2024 | Epidiolex |
| Banner Life Sciences, LLC | $130.81 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $124.74 | 2025 | Zeposia |
| Janssen Pharmaceuticals, INC | $122.90 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $121.66 | 2020-2025 | Onpattro |
| Ani Pharmaceuticals, INC. | $120.61 | 2023-2025 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $116.40 | 2021-2025 | Xeomin |
| Merz North America, INC. | $111.65 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $104.76 | 2019-2022 | |
| Greenwich Biosciences, INC. | $95.09 | 2019-2021 | |
| Axsome Therapeutics, INC. | $84.59 | 2023-2025 | Symbravo, Sunosi |
| Catalyst Pharmaceuticals, INC. | $81.88 | 2021-2024 | Fycompa, Firdapse |
| Otsuka America Pharmaceutical, INC. | $73.81 | 2023-2025 | Rexulti |
| Cycle Pharmaceuticals INC | $69.98 | 2025 | Tascenso Odt, Bafiertam |
| Abbott Laboratories | $66.92 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $59.85 | 2022-2025 | Qelbree |
| Immedica Pharma US, INC. | $59.67 | 2024 | |
| Acorda Therapeutics, INC | $57.25 | 2019-2024 | Inbrija, Ampyra |
| Impel Pharmaceuticals INC. | $55.93 | 2022-2023 | Trudhesa |
| Astrazeneca Pharmaceuticals LP | $51.03 | 2022-2025 | Wainua |
| Life Molecular Imaging LTD | $48.45 | 2025 | Neuraceq |
| Promius Pharma LLC | $39.06 | 2019 | |
| Sumitomo Pharma America, INC. | $32.83 | 2023 | Aptiom |
| Genentech, INC. | $30.65 | 2023 | Ocrevus |
| Microtransponder, INC. | $28.63 | 2025 | |
| Springworks Therapeutics, INC. | $25.83 | 2025 | Gomekli |
| Ipsen Biopharmaceuticals, INC | $22.13 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $22.09 | 2024 | Lumryz |
| Bausch Health US, LLC | $18.86 | 2019 | |
| Averitas Pharma INC. | $18.78 | 2025 | Qutenza |
| Assertio Therapeutics, INC. | $17.40 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.77 | 2024 | Hyqvia |
| Mallinckrodt Enterprises LLC | $16.61 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.45 | 2022 | |
| Corium, LLC | $15.20 | 2023 | Adlarity |
| Livanova USA, INC. | $14.90 | 2022 | |
| Adamas Pharmaceuticals, INC. | $14.88 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.75 | 2020 | |
| Ge Healthcare | $13.71 | 2019 | |
| Avion Pharmaceuticals | $13.67 | 2022 | |
| Horizon Therapeutics Plc | $13.03 | 2022 | |
| Currax Pharmaceuticals LLC | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.